Geron Corporation

431 articles about Geron Corporation

• Geron Presents Investor Event Highlights

  11/9/2021

  Geron Corporation, a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9.

• Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

  11/4/2021

  Geron Corporation today announced that three abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021.

• Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat

  10/25/2021

  Geron Corporation announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway launched in the United Kingdom by the Medicines and Healthcare products Regulatory Agency in January 2021, post-Brexit.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 21, 2021

  10/21/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 80,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

  10/18/2021

  Geron Corporation (Nasdaq: GERN), today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

• Geron to Host a Virtual Investor Event in November

  10/15/2021

  Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET. Topics to be covered at the event.

• Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

  10/11/2021

  Geron Corporation today announced the publication in the Annals of Hematology of a paper entitled “Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data”

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 16, 2021

  9/16/2021

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

• Geron Announces September Investor Conference Presentation Webcasts

  9/1/2021

  Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 19, 2021

  8/19/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 550,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023

  8/16/2021

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2021.

• Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

  8/5/2021

  Geron Corporation announced that it will release its second quarter and year to date 2021 financial results after the market closes on Monday, August 16, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 22, 2021

  7/22/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology

  6/17/2021

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.”

• Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress

  6/14/2021

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, are now available on Geron’s website as well as to participants of the EHA2021 Virtual Congress.

• Geron to Announce First Quarter 2021 Financial Results on May 10, 2021

  5/3/2021

  Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 22, 2021

  4/22/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 220,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

  4/13/2021

  Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 18, 2021

  3/18/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

  3/1/2021

  Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors .